跳至主要内容
临床试验/NCT07207239
NCT07207239Enrolling By Invitation不适用

Effect of Theta-burst rTMS Therapy on the Clinical and Cognitive Symptoms of Patients With Therapy Resistant Depression and Response Prediction With Neuroimaging Methods.

Semmelweis University2 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2025年6月13日最近更新:

试验速览

阶段
不适用
状态
Enrolling By Invitation
入组人数
54
试验地点
2
主要终点
Clinical symptoms

研究概览

简要总结

The primary aim of the study is to find the combination of neuroimaging-related markers, demographics, and clinical characteristics that predict the response of patients with therapy-resistant depression to theta-burst rTMS treatment. The secondary aim is to monitor the cognitive effects of TMS therapy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Screening
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • diagnosis of depression
  • 18 years of age
  • Beck depression inventory score above 12 (screening)
  • MADRS score above 6 (baseline)

排除标准

  • serious cognitive impairment
  • mental retardation
  • history of head injury with loss of consciousness for more than 1 hour
  • alcohol or drug abuse within the past 3 months

结局指标

主要结局

Clinical symptoms

时间窗: 120 days

The primary outcome measures are the clinical symptoms of depression measured by a clinician with the Montgomery-Åsberg Depression Rating Scale.

次要结局

  • Neuroimaging characteristics(120 days)
  • Patient profile(120 days)
  • Cognitive functioning/Spatial working Memory(120 days)
  • Cognitive functioning/Executive function(120 days)
  • Cognitive functioning/reaction time(120 days)
  • Clinical symptoms based on self-report questionnaires(120 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gábor Csukly

Associate Professor

Semmelweis University

研究点 (2)

Loading locations...

相似试验